154 related articles for article (PubMed ID: 22687642)
21. Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.
Bi Y; Zhang B; Xu W; Yang H; Feng W; Li C; Tong G; Li M; Wang X; Shen S; Zhu B; Weng J; Zhu D
Acta Diabetol; 2014 Oct; 51(5):865-73. PubMed ID: 25118999
[TBL] [Abstract][Full Text] [Related]
22. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
23. Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes.
Shand B; Scott R; Connolly S; Clarke R; Baker J; Elder P; Frampton C; Yeo J
Diabetes Obes Metab; 2007 Jul; 9(4):540-7. PubMed ID: 17587396
[TBL] [Abstract][Full Text] [Related]
24. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
Fernandez M; Triplitt C; Wajcberg E; Sriwijilkamol AA; Musi N; Cusi K; DeFronzo R; Cersosimo E
Diabetes Care; 2008 Jan; 31(1):121-7. PubMed ID: 17909084
[TBL] [Abstract][Full Text] [Related]
25. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
Derosa G; Fogari E; Cicero AF; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Gravina A; Ferrari I; Fogari R
Hypertens Res; 2007 May; 30(5):387-94. PubMed ID: 17587750
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
Stringer F; DeJongh J; Enya K; Koumura E; Danhof M; Kaku K
Diabetes Technol Ther; 2015 Mar; 17(3):215-23. PubMed ID: 25531677
[TBL] [Abstract][Full Text] [Related]
27. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
28. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
Mori Y; Itoh Y; Obata T; Tajima N
Endocrine; 2006 Feb; 29(1):143-8. PubMed ID: 16622303
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Gomis R; Espadero RM; Jones R; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2011 Jul; 13(7):653-61. PubMed ID: 21410628
[TBL] [Abstract][Full Text] [Related]
30. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
[TBL] [Abstract][Full Text] [Related]
31. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
[TBL] [Abstract][Full Text] [Related]
32. [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
Rodríguez A; Reviriego J; Polavieja P; Mesa J
Med Clin (Barc); 2008 Nov; 131(19):721-30. PubMed ID: 19091199
[TBL] [Abstract][Full Text] [Related]
33. CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Di Prospero NA; Artis E; Andrade-Gordon P; Johnson DL; Vaccaro N; Xi L; Rothenberg P
Diabetes Obes Metab; 2014 Nov; 16(11):1055-64. PubMed ID: 24798870
[TBL] [Abstract][Full Text] [Related]
34. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Kaku K; Itayasu T; Hiroi S; Hirayama M; Seino Y
Diabetes Obes Metab; 2011 Nov; 13(11):1028-35. PubMed ID: 21682833
[TBL] [Abstract][Full Text] [Related]
36. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
[TBL] [Abstract][Full Text] [Related]
37. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
Erem C; Ozbas HM; Nuhoglu I; Deger O; Civan N; Ersoz HO
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):295-302. PubMed ID: 24710641
[TBL] [Abstract][Full Text] [Related]
38. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
Erdem G; Dogru T; Tasci I; Bozoglu E; Muhsiroglu O; Tapan S; Ercin CN; Sonmez A
Diabetes Res Clin Pract; 2008 Nov; 82(2):214-8. PubMed ID: 18778865
[TBL] [Abstract][Full Text] [Related]
39. A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus.
Chou HS; Truitt KE; Moberly JB; Merante D; Choi Y; Mun Y; Pfützner A
Diabetes Obes Metab; 2012 Nov; 14(11):1000-9. PubMed ID: 22686944
[TBL] [Abstract][Full Text] [Related]
40. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat.
Birnbaum Y; Ye Y; Lin Y; Freeberg SY; Nishi SP; Martinez JD; Huang MH; Uretsky BF; Perez-Polo JR
Circulation; 2006 Aug; 114(9):929-35. PubMed ID: 16908763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
